FMT to Eradicate Intestinal Colonization by Carbapenem-resistant Enterobacteriaceae

Launched by FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS · Mar 28, 2023

Keywords

ClinConnect Summary

This clinical trial is investigating a treatment called fecal microbiota transplant (FMT) to help eliminate harmful bacteria in the gut known as carbapenem-resistant Enterobacteriaceae (CRE), which are difficult to treat due to antibiotic resistance. Antibiotic resistance is a significant health issue, and researchers believe that FMT, which involves transferring healthy bacteria from a donor’s stool to a patient’s gut, could be an effective way to restore a healthy balance and fight these infections.

To participate in this study, individuals must be 18 years or older and have been diagnosed with CRE through a rectal swab within the last 15 days. However, there are a few reasons someone might not be eligible, such as having certain gastrointestinal disorders, having had major surgery on the colon, or being pregnant. Those who join the trial can expect to undergo specific procedures to help evaluate the effectiveness of the treatment. This study is currently recruiting participants, and the goal is to better understand how FMT can help combat antibiotic-resistant infections while ensuring safety and efficacy.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • \>18 years;
• • CRE diagnosed with rectal swab \<15 days before evaluation;
• • Ability to undergo study procedures and to give informed consent.
• Exclusion Criteria:
• • Active chronic gastrointestinal disorders;
• • Previous colorectal surgery;
• • Major comorbidities;
• • Pregnancy/breastfeeding;
• • Psychiatric disorders.